rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
6
|
pubmed:dateCreated |
2007-9-10
|
pubmed:abstractText |
Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome. The current study was designed to determine whether etanercept (a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75-kilodalton TNF receptor linked to the Fc portion of human immunoglobulin [Ig] G1) could palliate this syndrome.
|
pubmed:grant |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0008-543X
|
pubmed:author |
pubmed-author:DakhilShaker RSR,
pubmed-author:FitchTom RTR,
pubmed-author:JatoiAminahA,
pubmed-author:KuglerJohn WJW,
pubmed-author:LoprinziCharles LCL,
pubmed-author:NguyenPhuong LPL,
pubmed-author:NovotnyPaul JPJ,
pubmed-author:RowlandKendrith MKMJr,
pubmed-author:SloanJeff AJA,
pubmed-author:SooriGamini SGS,
pubmed-author:WenderDonald BDB
|
pubmed:copyrightInfo |
(c) 2007 American Cancer Society.
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
110
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1396-403
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:17674351-Adult,
pubmed-meshheading:17674351-Aged,
pubmed-meshheading:17674351-Aged, 80 and over,
pubmed-meshheading:17674351-Anorexia,
pubmed-meshheading:17674351-Antineoplastic Agents,
pubmed-meshheading:17674351-Appetite,
pubmed-meshheading:17674351-Double-Blind Method,
pubmed-meshheading:17674351-Female,
pubmed-meshheading:17674351-Genotype,
pubmed-meshheading:17674351-Humans,
pubmed-meshheading:17674351-Immunoglobulin G,
pubmed-meshheading:17674351-Immunologic Factors,
pubmed-meshheading:17674351-Male,
pubmed-meshheading:17674351-Middle Aged,
pubmed-meshheading:17674351-Neoplasms,
pubmed-meshheading:17674351-Palliative Care,
pubmed-meshheading:17674351-Quality of Life,
pubmed-meshheading:17674351-Questionnaires,
pubmed-meshheading:17674351-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:17674351-Survival Analysis,
pubmed-meshheading:17674351-Treatment Outcome,
pubmed-meshheading:17674351-Tumor Necrosis Factor-alpha,
pubmed-meshheading:17674351-Weight Gain,
pubmed-meshheading:17674351-Weight Loss
|
pubmed:year |
2007
|
pubmed:articleTitle |
A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.
|
pubmed:affiliation |
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA. jatoi.aminah@mayo.edu
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|